Literature DB >> 21277392

Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease.

David H Bruining1, William J Sandborn.   

Abstract

It is a challenge to monitor patients with Crohn's disease who remain symptomatic despite anti-tumor necrosis factor therapy. Clinicians must use a systematic approach for each patient and obtain objective evidence about disease activity and response to therapy. Alternate etiologies for symptoms should be sought and treated, if found. Active Crohn's disease despite therapy requires reassessment and adjustments to management plans.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21277392     DOI: 10.1016/j.cgh.2011.01.019

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  4 in total

1.  Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease.

Authors:  Heba N Iskandar; Benjamin Cassell; Navya Kanuri; C Prakash Gyawali; Alexandra Gutierrez; Themistocles Dassopoulos; Matthew A Ciorba; Gregory S Sayuk
Journal:  J Clin Gastroenterol       Date:  2014 May-Jun       Impact factor: 3.062

Review 2.  Diagnosis and management of functional symptoms in inflammatory bowel disease in remission.

Authors:  Carlos Teruel; Elena Garrido; Francisco Mesonero
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

3.  Evaluation of Gastrointestinal Patient Reported Outcomes Measurement Information System (GI-PROMIS) Symptom Scales in Subjects With Inflammatory Bowel Diseases.

Authors:  Bharati Kochar; Christopher F Martin; Michael D Kappelman; Brennan M Spiegel; Wenli Chen; Robert S Sandler; Millie D Long
Journal:  Am J Gastroenterol       Date:  2017-08-29       Impact factor: 10.864

4.  Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response.

Authors:  Gary R Lichtenstein
Journal:  Therap Adv Gastroenterol       Date:  2013-07       Impact factor: 4.409

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.